News

ACC.20/WCC: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF
March 30, 2020
Top-line Results for GALACTIC-HF Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif., March 30, 2020 — Cytokinetics, Incorporated today announced that patient baseline characteristics and demographics from GALACTIC-HF (
ACC.20/WCC – REDUCE-IT Substudy: Boosts in Serum EPA Levels from Prescription Fish Oil Drive Heart Benefits
March 30, 2020
As with lowering LDL, raising EPA with icosapent ethyl helped lower CVD risk, study finds WASHINGTON (Mar 30, 2020) - Higher levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) found in the blood—and not a decrease in triglyceride levels as originally thought—appear to explain the striking reductions in cardiovascular events and deaths seen among people takin
ACC.20/WCC – CIAO: Chest Pain, Stress Tests Warrant Attention Even If Arteries Are Clear
March 30, 2020
Symptoms and test findings show tendency to ebb and flow, but still raise risk WASHINGTON (Mar 30, 2020) - Patients who experience chest pain and have abnormal results on a cardiac stress test but who do not have blocked arteries often experience changes in their symptoms and stress test results over time, according to research presented at the American College of Car
ACC.20/WCC: E-Cigarettes More Effective Than Counseling Alone for Smoking Cessation
March 30, 2020
Vaping significantly improved quit rate and reduced number of daily cigarettes at 12 weeks WASHINGTON (Mar 30, 2020) - Smokers who received smoking cessation counseling and used electronic cigarettes (e-cigarettes) containing nicotine were more than twice as likely to successfully quit smoking compared to those who received counseling but did not use e-cigarettes, in
ACC.20/WCC: Evinacumab Cuts Cholesterol Levels by Half in Patients with HoFH
March 30, 2020
Monoclonal antibody effective for the full spectrum of homozygous familial hypercholesterolemia WASHINGTON (Mar 30, 2020) - The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol to near-normal levels among patients with a rare cholesterol disorder, meeting the primary endpoint in the first randomized placebo-controlled trial of the drug
ACC.20/WCC: Alirocumab Substantially Reduces Cholesterol in Adult Patients with HoFH
March 30, 2020
PCSK9 inhibitor evaluated for treating homozygous familial hypercholesterolemia WASHINGTON (Mar 30, 2020) - The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a phase three clinical trial presented at the American College of
ACC.20/WCC: Ticagrelor Reduced Bleeding Vs Dual Therapy in High-Risk Coronary Patients in Sub-Analyses From Phase IV TWILIGHT Trial
March 30, 2020
…
ACC.20/WCC: Medtronic Onyx ONE Clear Study of One-Month Dual-Antiplatelet Therapy in High Bleeding Risk Stent Patients Beats Performance Goal
March 30, 2020
…
FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients with Chronic Kidney Disease
March 30, 2020
…
ACC.20/WCC – RADIAL: Use of Radial Artery in Heart Bypass Surgery Improves Patient Outcomes
March 30, 2020
Data from pooled analysis of clinical trials supports alternate approach WASHINGTON (Mar 29, 2020) - Patients undergoing heart bypass surgery lived longer and had better outcomes when surgeons used a segment of an artery from their arm, called the radial artery, instead of a vein from their leg, called the saphenous vein, to create a second bypass, according to resear